Login or Register to unlock everything MedSchool has to offer!

#

A

B

C

D

E

F

G

H

I

K

L

M

N

O

P

Q

R

S

T

U

V

W

Z

 

Tofacitinib

  •  
    Oral
    Tofacitinib
    Xeljanz 
     
    Inhibits JAK1, JAK2 and JAK3
    • Mechanism of Action
    • Inhibits Janus Kinases (JAK1, JAK2 and JAK3), a group of non-receptor tyrosine kinases involved in signalling downstream to cytokine receptors in immune and haematopoietic cells.

Clinical Use

    • Indication
    • Moderate to severe rheumatoid arthritis refractory to methotrexate.
    • Adverse Effects
    • Severe infections (particularly respiratory and urinary tract infections)
    • Anaemia
    • Headache
    • Dizziness
    • Nausea / vomiting / diarrhoea
    • Hypertension
    • Hypercholesterolaemia
    • Abdominal pain

Potential Indications
BETA

Rheumatoid Arthritis

Associated Adverse Effects
BETA

Secondary Hypertension
Secondary Hypertension
Secondary Hyperlipidaemia
Secondary Hyperlipidaemia
Feedback